Navigation Links
YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Date:8/19/2007

MISSISSAUGA, ON, Aug. 17 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announces that the information required to be disclosed in accordance with Rule 26 of the AIM Rules for Companies is available in the "Shareholder Information/Rule 26 Disclosures" section on the Company's home page, http://www.ymbiosciences.com.

About YM BioSciences

YM BioSciences Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients worldwide. The Company has two late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) for which recruitment in a Phase III trial in pediatric glioma has just been completed and which is approved in several countries for treatment of various types of head and neck cancer; and AeroLEF(TM), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment o
'/>"/>

SOURCE YM BioSciences Inc.

Copyright©2007 PR Newswire.

Page: 1 2

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
(Date:7/24/2014)... Gain recognition for leadership and ... the biotech industry. Nominations are now being accepted ... you by the Bio Supply Management Alliance ... management professionals for the past 7 years. , ... Biotech industry – Manufacturers, Service Providers, Material Suppliers, ...
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, announced today that ... presentation to investors on Tuesday, July 29, 2014, ... presentation will include an overview of Asterias, business ... webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 ...
(Date:7/24/2014)... rely on sophisticated equipment, trained personnel, and detection ... against terrorist attacks. A revolutionary new electronic chip ... their job much easier. , The groundbreaking nanotechnology-inspired ... Aviv University ,s School of Chemistry and Center ... Herzliya company Tracense, picks up the scent of ...
Breaking Biology Technology:Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4Nano-sized chip 'sniffs out' explosives far better than trained dogs 2
... Jessica N Ebright 1 and Catherine Bowes Rickman 1, 2, ... Biology, Duke University Medical Center, Durham, , NC 27710 ... , Duke University Medical Center, Box 3802, Durham, NC ... bowes007@duke.edu , , ...
... Julio E Celis 1 , Morten stergaard 1 , Pamela Celis 1 , Hanne ... 2 , 1 Department of Medical Biochemistry ... University of Aarhus, Aarhus, Denmark , 2 Department ... Bladder cancer comprises a broad spectrum of tumors that includes ...
... Diana Davis, Aiguo Zhang, Jim Torrence, and Emily Dale, Bio-Rad Laboratories,Inc., 2000 Alfred Nobel ... Introduction , ... The concentrations of analytes in these assays ... standard curve. A regression analysis is performed to derive , ...
Cached Biology Technology:Rapid, Reproducible Real-Time Quantitative RT-PCR Using the iCycler iQ Real-Time PCR Detection System and iQ Supermix, Rev A 2Rapid, Reproducible Real-Time Quantitative RT-PCR Using the iCycler iQ Real-Time PCR Detection System and iQ Supermix, Rev A 3Rapid, Reproducible Real-Time Quantitative RT-PCR Using the iCycler iQ Real-Time PCR Detection System and iQ Supermix, Rev A 4Rapid, Reproducible Real-Time Quantitative RT-PCR Using the iCycler iQ Real-Time PCR Detection System and iQ Supermix, Rev A 5Rapid, Reproducible Real-Time Quantitative RT-PCR Using the iCycler iQ Real-Time PCR Detection System and iQ Supermix, Rev A 6Rapid, Reproducible Real-Time Quantitative RT-PCR Using the iCycler iQ Real-Time PCR Detection System and iQ Supermix, Rev A 7Rapid, Reproducible Real-Time Quantitative RT-PCR Using the iCycler iQ Real-Time PCR Detection System and iQ Supermix, Rev A 8Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 2Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 3Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 4Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 5Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 6Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 7Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 8Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 9Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 10Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 11Selection of Standards for Bio-Plex Cytokine Assays, Rev A 2Selection of Standards for Bio-Plex Cytokine Assays, Rev A 3Selection of Standards for Bio-Plex Cytokine Assays, Rev A 4Selection of Standards for Bio-Plex Cytokine Assays, Rev A 5Selection of Standards for Bio-Plex Cytokine Assays, Rev A 6Selection of Standards for Bio-Plex Cytokine Assays, Rev A 7Selection of Standards for Bio-Plex Cytokine Assays, Rev A 8
(Date:7/25/2014)... Ravi Birla, associate professor of biomedical engineering at ... textbook on tissue engineering and artificial organ development., ... a comprehensive guide to entering into the field ... and professor of biomedical engineering at UH, served ... said that while there are other published books ...
(Date:7/25/2014)... a complex congenital central nervous system disease that ... neural tubes during the embryonic phase. Many patients ... incontinence and neurocognitive retardation. Such problems decrease the ... Researchers at Ankara Physical Medicine and Rehabilitation Education ... in children with SB, using the Pediatric Evaluation ...
(Date:7/25/2014)... The routine use of a molecular testing panel ... performing the correct initial surgery for patients with ... University of Pittsburgh Cancer Institute (UPCI), partner with ... Multidisciplinary Thyroid Center and other diagnostic testing agencies, ... initial surgery by 30 percent, according to the ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3
... Researchers at Albert Einstein College of Medicine of Yeshiva ... single gene in living cells. In an unprecedented study, published in ... were able to follow, in real time, the process of gene ... molecules of messenger RNA (mRNA) that go on to ...
... A study of DNA rearrangements in roundworm chromosomes may offer ... tumors. A report of the research led by University ... was published in the April 22 online edition of the ... region of repetitive DNA sequence that protects the ends of ...
... Infection Research (HZI) in Braunschweig, Germany have discovered a new, ... cells: In this entry mode, the bacteria exploit the muscle ... cytoplasm. Thus, the strategies Salmonella use to infect ... World Health Organization, the number of Salmonella infections ...
Cached Biology News:Scientists observe single gene activity in living cells 2Study in roundworm chromosomes may offer new clues to tumor genome development 2Salmonella utilize multiple modes of infection 2
ERalpha (Ser 104/106)...
... while maintaining high cell viability , ... , Fast: less than one ... , Highly reproducible results from ... with the Bio-Rad Gene Pulser Xcell System ...
Agarose, pulse field, 250 g. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1800 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Mouse CXCR3 Allophycocyanin MAb (Clone 220803)...
Biology Products: